Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could spot hidden heart damage in preeclampsia

NCT ID NCT07463898

Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This study looks for proteins in the blood that might show early heart changes in women with preeclampsia, a serious pregnancy condition. Researchers will also use heart ultrasounds to see how the heart changes during pregnancy. The goal is to find ways to predict future heart problems in these women. About 172 pregnant women will participate, providing blood samples and having heart scans at two points during their pregnancy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to detect early heart strain in women with preeclampsia, helping prevent long-term heart problems.
What could go wrong
This is an early observational study, not a treatment trial. It may not find clear markers, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 172 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be enrolled from primary health centers, and who are co-enrolled in the ENHANCE-CVH trial.

Ages

13 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Pregnant women who are up to 20 weeks pregnant * Able to consent to participate in the study * Are enrolled in the ENHANCE-CVH study * Willing to undergo echocardiography and blood draws Exclusion Criteria: * • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \[CAD\]) * Sickle cell disease * Pulmonary arterial hypertension * Pulmonary embolism * Inability to provide informed consent * Acute Illness * Malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular biomarkers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular biomarkers Preeclampsia (PE) Preeclampsia (PE) risk

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Abuja Teaching Hospital

    RECRUITING

    Abuja, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.